AOP-Wiki

API

All Key Events

Showing 1701 to 1725 of 1939 Key Events

ID	Title	Event Component Count	Biological Organization	Created At	Last Updated	AOPs

484	Activation, AKT2 Short Name Activation, AKT2	1	Molecular	Nov 29, 2016	Sep 16, 2017	62: AKT2 activation leading to hepatic steatosis
483	Activation, LXR alpha Short Name Activation, LXR alpha	1	Molecular	Nov 29, 2016	Sep 16, 2017	61: NFE2L2/FXR activation leading to hepatic steatosis
482	Decreased, DHB4/HSD17B4 Short Name Decreased, DHB4/HSD17B4	1	Molecular	Nov 29, 2016	Sep 16, 2017	61: NFE2L2/FXR activation leading to hepatic steatosis
480	Activation, SHP Short Name Activation, SHP	1	Molecular	Nov 29, 2016	Sep 16, 2017	61: NFE2L2/FXR activation leading to hepatic steatosis
479	Activation, NR1H4 Short Name Activation, NR1H4	1	Molecular	Nov 29, 2016	Sep 16, 2017	61: NFE2L2/FXR activation leading to hepatic steatosis
478	Activation, NRF2 Short Name Activation, NRF2	1	Molecular	Nov 29, 2016	Sep 16, 2017	61: NFE2L2/FXR activation leading to hepatic steatosis
477	Decreased, Ketogenesis Short Name Decreased, Ketogenesis	1	Cellular	Nov 29, 2016	Sep 16, 2017	60: NR1I2 (Pregnane X Receptor, PXR) activation leading to hepatic steatosis
474	Down Regulation, HMGCS2 Short Name Down Regulation, HMGCS2	1	Molecular	Nov 29, 2016	Sep 16, 2017	60: NR1I2 (Pregnane X Receptor, PXR) activation leading to hepatic steatosis
472	Down Regulation, CPT1A Short Name Down Regulation, CPT1A	1	Molecular	Nov 29, 2016	Sep 16, 2017	2 AOPs 60: NR1I2 (Pregnane X Receptor, PXR) activation leading to hepatic steatosis 401: G protein-coupled estrogen receptor 1 (GPER) signal pathway in the lipid metabolism disrupting effects
471	Inhibition, FoxA2 Short Name Inhibition, FoxA2	1	Molecular	Nov 29, 2016	Sep 16, 2017	60: NR1I2 (Pregnane X Receptor, PXR) activation leading to hepatic steatosis
470	Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1) Short Name	1	Molecular	Nov 29, 2016	Sep 16, 2017	58: NR1I3 (CAR) suppression leading to hepatic steatosis
468	Inhibition, PPAR alpha Short Name Inhibition, PPAR alpha	1	Molecular	Nov 29, 2016	Sep 16, 2017	58: NR1I3 (CAR) suppression leading to hepatic steatosis
467	Increased, LDL uptake Short Name Increased, LDL uptake	1	Cellular	Nov 29, 2016	Sep 16, 2017	2 AOPs 57: AhR activation leading to hepatic steatosis 462: Activation of reactive oxygen species leading the atherosclerosis
466	Up Regulation, LDLR (low density lipoprotein receptor) Short Name	1	Molecular	Nov 29, 2016	Sep 16, 2017	57: AhR activation leading to hepatic steatosis
465	Increased, Fatty acid influx Short Name Increased, FA Influx	1	Cellular	Nov 29, 2016	Feb 24, 2026	6 AOPs 57: AhR activation leading to hepatic steatosis 60: NR1I2 (Pregnane X Receptor, PXR) activation leading to hepatic steatosis 58: NR1I3 (CAR) suppression leading to hepatic steatosis 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress
463	Up Regulation, FAS Short Name Up Regulation, FAS	1	Molecular	Nov 29, 2016	Sep 16, 2017	58: NR1I3 (CAR) suppression leading to hepatic steatosis
462	Up Regulation, SCD-1 Short Name Up Regulation, SCD-1	1	Molecular	Nov 29, 2016	Sep 16, 2017	4 AOPs 58: NR1I3 (CAR) suppression leading to hepatic steatosis 60: NR1I2 (Pregnane X Receptor, PXR) activation leading to hepatic steatosis 57: AhR activation leading to hepatic steatosis 401: G protein-coupled estrogen receptor 1 (GPER) signal pathway in the lipid metabolism disrupting effects
461	Suppression, HNF4alpha Short Name Suppression, HNF4alpha	1	Molecular	Nov 29, 2016	Sep 16, 2017	59: HNF4alpha suppression leading to hepatic steatosis
460	Increased, Fatty acid uptake Short Name Increased, Fatty acid uptake	0	Cellular	Nov 29, 2016	Dec 3, 2016	None
459	Increase, Liver steatosis Short Name Increase, Liver steatosis	1	Organ	Nov 29, 2016	Feb 11, 2026	21 AOPs 58: NR1I3 (CAR) suppression leading to hepatic steatosis 60: NR1I2 (Pregnane X Receptor, PXR) activation leading to hepatic steatosis 61: NFE2L2/FXR activation leading to hepatic steatosis 62: AKT2 activation leading to hepatic steatosis 36: Peroxisomal Fatty Acid Beta-Oxidation Inhibition Leading to Steatosis 213: Inhibition of fatty acid beta oxidation leading to nonalcoholic steatohepatitis (NASH) 285: Inhibition of N-linked glycosylation leads to liver injury 318: Glucocorticoid Receptor activation leading to hepatic steatosis 517: Pregnane X Receptor (PXR) activation leads to liver steatosis 518: Liver X Receptor (LXR) activation leads to liver steatosis 529: Xenobiotic binding to peroxisome proliferator-activated receptors (PPARs) causes dysregulation of lipid metabolism leading to liver steatosis 232: NFE2/Nrf2 repression to steatosis 57: AhR activation leading to hepatic steatosis 494: AhR activation leading to liver fibrosis 591: DBDPE-induced DNA damage increase in liver leading to Non-alcoholic fatty liver disease via liver steatosis and inhibition of regeneration 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress
458	Increased, De Novo FA synthesis Short Name Increased, De Novo FA synthesis	1	Cellular	Nov 29, 2016	Sep 16, 2017	2 AOPs 58: NR1I3 (CAR) suppression leading to hepatic steatosis 61: NFE2L2/FXR activation leading to hepatic steatosis
457	Activation, SREBF1 Short Name Activation, SREBF1	2	Molecular	Nov 29, 2016	Sep 16, 2017	2 AOPs 58: NR1I3 (CAR) suppression leading to hepatic steatosis 62: AKT2 activation leading to hepatic steatosis
456	Suppression, Constitutive androstane receptor, NR1I3 Short Name	1	Molecular	Nov 29, 2016	May 25, 2026	58: NR1I3 (CAR) suppression leading to hepatic steatosis
454	Increased, Triglyceride formation Short Name Increased, Triglyceride formation	2	Cellular	Nov 29, 2016	Sep 16, 2017	2 AOPs 58: NR1I3 (CAR) suppression leading to hepatic steatosis 60: NR1I2 (Pregnane X Receptor, PXR) activation leading to hepatic steatosis
451	Inhibition, Mitochondrial fatty acid beta-oxidation Short Name	1	Molecular	Nov 29, 2016	Sep 16, 2017	3 AOPs 57: AhR activation leading to hepatic steatosis 58: NR1I3 (CAR) suppression leading to hepatic steatosis 61: NFE2L2/FXR activation leading to hepatic steatosis